Tempus AI: $11.45B valuation, IPO Readiness 74, Public. Filed S-1 with the SEC on January 2026 — IPO actively in progress. Track live on The IPO Stack.
AI-powered precision medicine platform analyzing clinical and molecular data.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Tempus AI IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Tempus AI is already a public company.
Tempus AI is valued at $11.45B as of June 2024. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Tempus AI is already a public company. You can invest by purchasing shares on public stock exchanges.
Tempus AI scores 74/100 (Grade: B) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Yes — Tempus AI filed an S-1 registration statement with the SEC on January 30, 2026, indicating an active IPO process.
Tempus AI has raised $1.55B in total venture capital and private equity funding, with backing from New Enterprise Associates, T. Rowe Price, Franklin Templeton.
Tempus AI's notable investors include New Enterprise Associates, T. Rowe Price, Franklin Templeton, Google, Baillie Gifford. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Tempus AI is a Biotechnology company. AI-powered precision medicine platform analyzing clinical and molecular data.